Genezen breaks ground on cGMP lentiviral vector production facility

Genezen Laboratories, Inc., a cell and gene therapy Contract Development and Manufacturing Organization (CDMO) focused on early-phase process development, vector production and analytical testing services, has broken ground on a new multiphase master plan for a 75,000+ square foot cGMP-compliant Lentiviral vector production facility.

ZEISS revolutionizes quantitative petrography

ZEISS introduces unique digitization system for virtual microscopy, collaboration and machine learning data analytics

Protheragen MedAI Offers Comprehensive Solutions for Drug Research and Development, Medical Imaging and Medical Therapy and Research System

BOC Sciences Completed Deployment of GMP Manufacturing Facilities to Promote Drug R&D

Shimmer Adopts the V3 Framework to Validate its Verisense® Wearable Sensing Platform for Clinical Trials

The Verisense IMU (inertial measurement unit) was the first Shimmer sensor validated following the V3 framework championed by the Digital Medicine Society (DiMe).

Samsung Biologics Issues Its First Annual Sustainability Report

Samsung Biologics (KRX: 207940.KS), the world’s leading contract development and manufacturing organization (CDMO), published its first annual sustainability report, consolidating the company’s policies for an enhanced ESG management system and related plans. The report focuses on the company’s commitment to taking part in social responsibility over the past decade and its future plans for the next ten years and beyond.

Watson-Marlow Fluid Technology Group wins Best Business Award

Watson-Marlow Fluid Technology Group announces it has been named winner of the Best Employer category at the 2021 Best Business Awards.

BRIM Biotechnology’s lead candidate BRM421 for Dry Eye Syndrome shows promising results in Phase II clinical trials

BRIM Biotechnology, Inc. is pleased to advise that the Type C meeting with the US Food and Drug Administration (FDA) for the further development of lead candidate BRM421 for Dry Eye Syndrome (DES) has taken place, and preparation to initiate Phase III trials in 2022, is underway.

Optibrium Publishes Major Peer-Reviewed Study on AI Applications to Global Pharma Data

Published in AI Letters, the study collaborators Optibrium, Takeda and Intellegens, demonstrated the application of deep learning imputation to a global pharma dataset, offering new insights into drug discovery data that transform how complex data can be used to identify opportunities for new drugs and streamline the drug discovery process.

CyncHealth Selects Lyniate to Support Rapid Growth and Community Collaboration 

Lyniate announces that it has been selected by CyncHealth to support its explosive growth throughout the Midwest.

CluePoints’ Launch Post-COVID Trial Assurance Solution

CluePoints, the premier provider of Risk-Based Quality Management Solutions for clinical trials, has launched a new Post-COVID Trial Assurance Solution as part of its mission to build safer, more efficient trials for patients, sponsors and CROs.

Bio-Gate and Avicanna complete first phase of development on CBD and Micro Silver BG™ based skin care products for global commercialization

About Bio-Gate: Bio-Gate AG is one of the world’s leading providers of innovative technologies and customised solutions for health and hygiene. Our aim is to make living together safer and healthier and to improve the well-being of all individuals. Bio-Gate enhances materials and products with its technologies and antimicrobial and antiviral strategies, and, thereby improves the quality of life of people and animals alike. The company specializes in equipping materials and surfaces with antiviral and antimicrobial properties. Bio-Gate AG enhances materials and products, particularly in the field of medical technology, such as the coating of implants or wound dressings. In addition, Bio-Gate technologies are used to provide consumer, industrial and hygiene products, such as paints, coatings, plastics or protective film sprays with antiviral and antimicrobial properties, thus enhancing them in a unique way. Bio-Gate also uses its unique and multi-functional additive MicroSilver BG in dermatology and cosmetics as well as wound care to provide these kind of products with long-lasting antimicrobial, anti-inflammatory and Microbiome friendly properties.

Stilla Technologies Strengthens Executive Team with Appointment of Matthew Grow, PhD, to Vice President Global Marketing and Commercial Operations

Stilla Technologies welcomes Dr. Matthew Grow on board as the company extends its global footprint in the digital PCR marketplace.

Metrics Contract Services Increases Capacity With New Equipment Investment

AARDEX Group and AdhereTech Partnership Boosts Medication Adherence with Software, Data Analytics and Smart Pill Bottle

Belgium-based AARDEX Group, the world leader in medication adherence solutions, today announced a strategic partnership with AdhereTech, an innovative company that improves the patient experience with real-time technology and Smart devices for optimal medication benefits.

CUREBASE UNLOCKS DRUG DEVELOPMENT WITH REMOTE CLINICAL TRIALS; RAISES $15M LED BY GGV CAPITAL

Curebase today announced $15M in Series A funding to continue developing its decentralized clinical trial software platform and virtual research site capabilities.

Torus Biosystems Announces $25 Million Series A Financing to Advance Infectious Disease Diagnostics Across Healthcare Settings New Funding to Support Development and Commercialization of Rapid, Molecular Point-of-Care Testing System

Torus Biosystems Announces $25 Million Series A Financing for syndromic testing solution designed for point-of-care use in ambulatory care settings such as hospital outpatient and emergency departments.

MDI Biological Laboratory Scientist Identifies Signaling Underlying Regeneration

A team of scientists led by James Godwin, Ph.D., of the MDI Biological Laboratory in Bar Harbor, Maine, has come a step closer to unraveling the mystery of why salamanders can regenerate while adult mammals cannot with the discovery of differences in molecular signaling that promote regeneration in the axolotl, a highly regenerative salamander, while blocking it in the adult mouse, a mammal like humans with limited regenerative ability. The discovery could open the door to pharmaceutical therapies that stimulate regeneration in tissues and organs lost to disease or injury.

Cotiviti Recognized by Both Stevie® 2021 American Business Awards and Fast Company World Changing Ideas Awards Programs

Cotiviti, a leading technology and analytics company, is honored for developing its COVID-19 Outbreak Tracker during the height of the pandemic to help forecast potentially hidden infection outbreaks.

Mission of Protheragen MedAI: to Seek Innovative Solutions for Drug Discovery and Life Science Research